References
- Agrawal R., Kusek J.W., Pappas M.K.: A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int., 2015; 88: 905–914
- Alamanos Y., Drosos A.A.: Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev., 2005; 4: 130–136
- Albaramki J., Hodson E.M., Craig J.C., Webster A.C.: Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst. Rev., 2012; 1: CD007857
- Allen R.P., Auerbach S., Bahrain H., Auerbach M., Earley C.J.: The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. Am. J. Hematol., 2013; 88: 261–264
- Anker S.D., Comin Colet J., Filippatos G., Wilenheimer R., Dickstein K., Drexler H., Lüscher T.F., Bart B., Banasiak W., Niegowska J., Kirwan B.A., Mori C.: Ferric carboxymaltose in patients with heart failure and iron deficiency. N. Eng. J. Med., 2009; 361: 2436–2448
- Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F. Cooper N.S., Healey L.A., Kaplan S.R., Liang M.H., Luthra H.S.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 1988; 31: 315–324
- Auerbach M., Adamson J.W.: How we diagnose and treat iron deficiency anemia. Am. J. Hematol., 2016; 91: 31–38
- Babitt J.L., Lin H.Y.: Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am. J. Kidney Dis., 2010; 55: 726–741
- Berner B., Akca D., Jung T., Muller G.A., Reuss-Borst M.A.: Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry. J. Rheumatol., 2000; 27: 1128–1135
- Beutler E., Waalen J.: The definition of anemia: What is the lower limit of normal of the blood hemoglobin concentration? Blood, 2006; 107: 1747–1750
- Blanchette N.L., Manz D.H., Torti F.M., Torti S.V.: Modulation of hepcidin to treat iron deregulation: Potential clinical applications. Expert. Rev. Hematol., 2016; 9: 169–186
- Bloxham E., Vagadia V., Scott K., Francis G., Saravanah V., Heycock C., Rynne M., Hamilton J., Kelly C.A.: Anaemia in rheumatoid arthritis: can we afford to ignore it? Postgrad. Med. J., 2011; 87: 596–600
- Bogdanos D.P., Smyk D.S., Rigopoulou E.I., Mytylinaiou M.G., Heneghan M.A., Selmi C., Gershwin M.E.: Twin studies in autoimmune disease: Genetics, gender and environment. J. Autoimmun., 2012; 38: J156–J169
- Calisto Peres C., Leon R., Leon F., Ng S.L.: Rheumatoid arthritis and anemia: the impact of different anti-inflammatory therapies on hemoglobin levels. An observational study. Bol. Asoc. Med. P. R., 2012; 104: 34–41
- Cappellini M.D., Comin-Colet J., de Francisco A., Dignass A., Doehner W., Lam C.S., Macdougall I.C., Rogler G., Camaschella C., Kadir R., Kassebaum N.J., Spahn D.R., Taher A.T., Musallam K.M.: Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am. J. Hematol., 2017; 92: 1068–1078
- Clark S.F.: Iron deficiency anemia: diagnosis and management. Curr. Opin. Gastroenterol., 2009; 25: 122–128
- Comin-Colet J., Lainscak M., Dickstein K., Filoppatos G.S., Johnson P., Lusher T.F., Mori C., Willenheimer R., Ponikowski P., Anker S.D.: The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: A subanalysis of the FAIR-HF study. Eur. Heart J., 2013; 34: 30–38
- Costenbader K.H., Chang S.C., DeVivo I., Plenge R., Karlson E.W.: Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: Evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res. Ther., 2008; 10: R52
- Daher R., Karim Z.: Iron metabolism: State of the art. Transfus. Clin. Biol., 2017; 24: 115–119
- Demirag M.D., Haznedaroglu S., Sancak B., Konca C., Gulbahar O., Ozturk M.A., Goker B.: Circulating hepcidin in the crossroads of anemia and inflammation associated with rheumatoid arthritis. Intern. Med., 2009; 48: 421–426
- De Falco L., Sanchez M., Silvestri L., Kannegiesser C., Muckenthaler M.U., Iolascon A., Gouya L., Camaschella C., Beaumont C.: Iron refractory iron deficiency anemia. Haematologica, 2013; 98: 845–853
- Di Giuseppe D., Discacciati A., Orsini N., Wolk A.: Cigarette smoking and risk of rheumatoid arthritis: A dose-response meta-analysis. Arthritis Res. Ther., 2014; 16: R61
- Enjuanes C., Klip I.T., Brugera J., Cladellas M., Ponikowski P., Banasiak W., van Veldhuisen D.J., van der Meer P., Jankowska E.A., Comín-Colet J.: Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. Int. J. Cardiol., 2014; 174: 268–275
- Fernandez-Rodriguez A.M., Guindeo-Casasus M.C., Molero-Labarta T., Dominguez-Cabrera C., Hortal-Casc L., Perez-Borges P., Vega-Díaz N., Saavedra-Santana P., Palop-Cubillo L.: Diagnosis of iron deficiency in chronic renal failure. Am. J. Kidney Dis., 1999; 34: 508–513
- Franchini M., Montagnana M., Lippi G.: Hepcidin and iron metabolism: From laboratory to clinical implications. Clin. Chim. Acta, 2010; 411: 1565–1569
- Fryc J., Sierakowski S.: Anaemia of chronic diseases in rheumatoid arthritis. Rheumatology, 2010; 48: 421–424
- Glant T.T., Mikecz K., Rauch T.A.: Epigenetics in the pathogenesis of rheumatoid arthritis. BMC Med., 2014; 12: 35
- Goodnough L.T., Maniatis A., Earnshaw P., Benoni G., Beris P., Bisbe E., Fergusson D.A, Gombotz H., Habler O., Monk T.G., Ozier Y., Slappendel R., Szpalski M.: Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br. J. Anaesth., 2011; 106: 13–22
- Goodnough L.T., Nemeth E., Ganz T.: Detection, evaluation, and management of iron-restricted erythropoiesis. Blood, 2010; 116: 4754–4761
- Goodnough L.T., Schrier S.L.: Evaluation and management of anemia in the elderly. Am. J. Hematol., 2014; 89: 88–96
- Hedge N., Rich M.W., Gayomali C.: The cardiomyopathy of iron deficiency. Tex. Heart Inst. J., 2006; 33: 340–344
- Jankowska E.A., Rozentryt P., Witkowska A., Nowak J., Hartmann O., Ponikowska B., Borodulin-Nadzieja L., Banasiak W., Polonski L., Filippatos G., McMurray J.J., Anker D., Ponikowski P.: Iron deficiency: an ominous sign in patients with systolic chronic heart failure. Eur. Heart J., 2010; 31: 1872–1880
- Jankowska E.A., von Heahling S., Anker S.D., Macdougal I.C., Ponikowski P.: Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur. Heart J., 2013; 34: 816–829
- Jimenez K., Kulnigg-Dabsch S., Gasche C.: Management of iron deficiency anemia. Gastroenterol. Hepatol., 2015; 11: 241–250
- Jones G., Sebba A., Gu J., Lowenstein M.B., Calvo A., Gomez-Reino J.J., Siri D.A., Tomsic M., Alecock E., Woodworth T., Genovese M.C.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis., 2010; 69: 88–96
- Kulnigg S., Gasche C.: Systematic review: managing anaemia in Crohn’s disease. Aliment. Pharmacol. Ther., 2006; 24: 1507–1523
- Lai Y., Dong C.: Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int. Immunol., 2016; 28: 181–188
- Lankhorst C.E., Wish J.B.: Anemia in renal disease: diagnosis and management. Blood Rev., 2010; 24: 39–47
- Macdougall I.C., Bircher A.J., Eckardt K.U., Obrador G.T., Pollock C.A., Steinvinkel P., Swinkels D.W., Wanner C., Weiss G., Chertow G.M.: Iron management in chronic kidney disease: Conclusions from a ‘Kidney Disease: Improving Global Outcomes’ (KDIGO) Controversies Conference. Kidney Int., 2016; 89: 28–39
- Macovei L.A., Brujbu I.C.: Clinical and epidemiological study on the prevalence of rheumatoid arthritis in some demographic structures. Rev. Med. Chir. Soc. Med. Nat. Iasi, 2013; 117: 747–753
- McLean E., Cogswell M., Egli I., Wojdyla D., de Benoist B.: Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr., 2009; 12: 444–454
- Miller J.L.: Iron deficiency anemia: a common and curable disease. Cold Spring Harb. Perspect. Med., 2013; 3: a011866
- Moldawer L.L., Marano M.A., Wei H., Fong Y., Silen M.L., Kuo G., Manogue K.R., Vlassara H., Cohen H., Cerami A.: Cachectin/tumor necrosis factor-α alters red blood cell kinetics and induces anemia in vivo. FASEB. J., 1989; 3: 1637–1643
- Nemeth E., Rivera S., Gabayan V., Keller C., Taudorf S., Pedersen B.K., Ganz T.: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest., 2004; 113: 1271–1276
- Neogi T., Aletaha D., Silman A.J., Naden R.L., Felson D.T., Aggrawal L., Bingham C.O., Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., Combe B., Costenbader K.H., Dougados M., Emery P., et al.: The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum., 2010; 62: 2582–2591
- Ohtsuji M., Lin Q., Nishikawa K., Ohtsuji N., Okazaki H., Tsurui H., Amano H., Shirai T., Nishimoto N., Nishimura H., Hirose S., et al.: IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model. Mod. Rheumatol., 2015; 25: 270–277
- Okada Y., Wu D., Trynka G., Raj T., Terao C., Ikari K., Kochi Y., Ohmura K., Suzuki A., Yoshida S., Graham R.R., Manoharan A., Ortmann W., Bhangale T., Denny J.C., et al.: Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature, 2014; 506: 376–381
- Okonko D.O., Grzeslo A., Witkowski T., Mandal A.K., Slater R.M., Roughton M., Foldes G., Thum T., Majda J., Banasiak W., Missouris C.G., Poole-Wilson P.A., Anker S.D., Ponikowski P., et al.: Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial. J. Am. Coll. Cardiol., 2008; 51: 103–112
- Okonko D.O., Mandal A.K., Missouris C.G., Poole-Wilson P.A.: Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival. J. Am. Coll. Cardiol., 2011; 58: 1241–1251
- Onken J.E., Bregman D.B., Harrington R.A., Morris D., Buerkert J., Hamerski D., Iftikhar H., Mangoo-Karim R., Martin E.R., Martinez C.O., Newman G.E., Qunibi W.Y., Ross D.L., Singh B., Smith M.T., et al.: Ferric carboxymaltose in patients with iron-deficiency anemia and impaired renal function: the REPAIR-IDA trial. Nephrol. Dial. Transplant., 2014; 29: 833–842
- Ponikowski P., van Veldhuisen D.J., Comin-Colet J., Ertl G., Komajda M., Mareev V., Parkhomenko A., Tavazzi L., Levesque V., Mori C., Roubert B., Filippatos G., Ruschitzka F., Anker S.D., CONFIRM-HF Investigators: Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur. Heart J., 2015; 36: 657–668
- Raj D.S.: Role of interleukin-6 in the anemia of chronic disease. Semin. Arthritis Rheum., 2009; 38: 382–388
- Reynolds G., Gibbon J.R., Pratt A.G., Wood M.J., Coady D., Raftery G., Lorenzi A.R., Gray A., Filer A., Buckley C.D., Haniffa M.A., Isaacs J.D., Hilkens C.M.: Synovial CD4+ T-cell-derived GM-CSF supports the differentiation of an inflammatory dendritic cell population in rheumatoid arthritis. Ann. Rheum. Dis., 2016; 75: 899–907
- Saito H.: Metabolism of iron stores. Nagoya J. Med. Sci., 2014; 76: 235–254
- Saito H., Hayashi H., Tomita A., Ohashi H., Maeda H., Naoe T.: Increasing and decreasing phases of ferritin and hemosiderin iron determined by serum ferritin kinetics. Nagoya J. Med. Sci., 2013; 75: 213–223
- Selmi C., Lu Q., Humble M.C.: Heritability versus the role of the environment in autoimmunity. J. Autoimmun., 2012; 39: 249–252
- Selmi C., Shoenfeld Y.: Open questions in autoimmunity: discussions from the 2013 Controversies in Rheumatology and Autoimmunity Meeting. BMC Med., 2014; 12: 50
- Shander A., Goodnough L.T., Javidroozi M., Auerbach M., Carson J., Ershler W.B., Ghiglione M., Glaspy J., Lew I.: Iron deficiency anemia – bridging the knowledge and practice gap. Transfus. Med. Rev., 2014; 28: 156–166
- Siebert S., Tsoukas A., Robertson J., McInnes I.: Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases. Pharmacol. Rev., 2015; 67: 280–309
- Smyrnowa G.: The relationship between hemoglobin level and disease activity in patients with rheumatoid arthritis. Rev. Bras. Reumatol., 2014; 54: 437–440 [Article in Portuguese]
- Song S.N., Iwahashi M., Tomosugi N., Uno K., Yamana J., Yamana S., Isobe T., Ito H., Kawabata H., Yoshizaki K.: Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Res. Ther., 2013; 15: R141
- Stancu S., Stanciu A., Zugravu A., Barsan L., Dumitry D., Lipan M., Mircescu G.: Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am. J. Kidney Dis., 2010; 55: 639–647
- Stein J., Bager P., Befrits R., Danese S., Gasche C., Lerebours E.: Current practice of anemia management in patients with inflammatory bowel disease across four European countries. Gastroenterology, 2011; 140: S556
- Sudol-Szopinska I., Kontny E., Maslinski W., Prochorec-Sobieszek M., Warczynska A., Kwiatkowska B.: Significance of bone marrow edema in pathogenesis of rheumatoid arthritis. Pol. J. Radiol., 2013; 78: 57–63
- Susantitaphong P., Alqahtani F., Jaber B.L.: Efficacy and safety of intravenous iron therapy for functional iron deficiency anemia in hemodialysis patients: A meta-analysis. Am. J. Nephrol., 2014; 39: 130–141
- Sy T., Jamal M.M.: Epidemiology of hepatitis C virus (HCV) infection. Int. J. Med. Sci., 2006; 3: 41–46
- Theurl I., Aigner E., Theurl M., Nairz M., Seifert M., Schroll A., Sonnweber T., Eberwein L., Witcher D.R., Murphy A.T., Wroblewski V.J., Wurz E., Datz C., Weiss G.: Regulation of iron homeostasis in anemia of chronic disease and iron deficiency anemia: Diagnostic and therapeutic implications. Blood, 2009; 113: 5277–5286
- Tobon G.J., Youinou P., Saraux A.: The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. J. Autoimmun., 2010; 35: 10–14
- Voulgari P.V., Kolios G., Papadopulos G.K., Katsaraki A., Seferiadis K., Drosos A.A.: Role of cytokines in the pathogenesis of anemia of chronic disease in rheumatoid arthritis. Clin. Immunol., 1999; 92: 153–160
- Weiss G., Goodnough L.T.: Anemia of chronic disease. N. Engl. J. Med., 2005; 352: 1011–1023
- Wetmore J.B., Peng Y., Jackson S., Malton T.J., Collins A.J., Gilbertson D.T.: Patient characteristics, disease burden, and medication use in stage 4–5 chronic kidney disease patients. Clin. Nephrol., 2016; 85: 101–111
- Wilson A., Yu H.T., Goodnough L.T., Nissenson A.R.: Prevalence and outcomes of anemia in rheumatoid arthritis: a systematic review of the literature. Am. J. Med., 2004; 116: 50S–57S
- Wish J.B.: Assessing iron status: Beyond serum ferritin and transferrin saturation. Clin. J. Am. Soc. Nephrol., 2006; 1 (Suppl.): S4–S8
- Zimmermann M.B., Hurrell R.F.: Nutritional iron deficiency. Lancet, 2007; 370: 511–520